Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, People's Republic of China.
Key Laboratory of Cancer Prevention and Therapy, Tianjin, People's Republic of China.
J Cancer Res Clin Oncol. 2023 Dec;149(18):16365-16376. doi: 10.1007/s00432-023-05371-0. Epub 2023 Sep 13.
Although targeted therapies and immunotherapy have achieved significant clinical benefits in patients with certain pathological types of lung cancer. However, prognosis for patients with lung adenocarcinoma still remains unsatisfactory. It is of extremely importance to find ideal prognostic indicators to predict the prognosis of lung adenocarcinoma patients, especially for patients with early and locally advanced-stage lung adenocarcinoma. The purpose of this study is to elucidate the significance of Insulin-like growth factor receptor 1 (IGFR1) and Vascular endothelial growth factor A (VEGF-A) expression in predicting progression-free survival (PFS) and overall survival (OS) in patients with early and locally advanced-stage lung adenocarcinoma.
In this study, IGFR1 and VEGF-A expression on 119 specimens of patients early and locally advanced-stage lung adenocarcinoma were analyzed by immunohistochemistry with an H-score system.
Both high IGFR1 expression and VEGF-A expression patients were resulted in 59 (49.6%) separately. The numbers and proportions of IGFR1&VEGF-A subgroup, IGFR1&VEGF-A subgroup, IGFR1&VEGF-A subgroup and IGFR1&VEGF-A subgroup are 23 (19.3%), 37 (31.1%), 37 (31.1%) and 22 (18.5%) respectively. High IGFR1 expression was significantly associated with both poor PFS and OS of all patients in a univariate analysis. Multivariable analysis showed that patients with IGFR1&VEGF-A expression exhibited a worst PFS and OS in the subgroup of lung adenocarcinoma patients with EGFR mutation.
These results suggest that IGFR1&VEGF-A is expected to be a disadvantageous factor for prognosis in the subgroup of EGFR mutation in patients with early and locally advanced-stage lung adenocarcinoma. What's more, this study may provide the theoretical possibility to screen optimal population for a combination therapy with anti-VEGF and anti-IGFR1 in patients with early and locally advanced-stage lung adenocarcinoma.
尽管针对某些特定病理类型的肺癌患者的靶向治疗和免疫治疗已取得显著的临床获益，但肺腺癌患者的预后仍不尽如人意。寻找理想的预后指标来预测肺腺癌患者的预后，特别是对于早期和局部晚期肺腺癌患者，至关重要。本研究旨在阐明胰岛素样生长因子受体 1（IGFR1）和血管内皮生长因子 A（VEGF-A）表达在预测早期和局部晚期肺腺癌患者无进展生存期（PFS）和总生存期（OS）中的意义。
本研究采用免疫组织化学 H 评分系统分析了 119 例早期和局部晚期肺腺癌患者标本中 IGFR1 和 VEGF-A 的表达。
分别有 59 例（49.6%）患者高表达 IGFR1 和 VEGF-A。IGFR1&VEGF-A 双高组、IGFR1 高表达组、VEGF-A 高表达组和 IGFR1 与 VEGF-A 均高表达组的例数和比例分别为 23 例（19.3%）、37 例（31.1%）、37 例（31.1%）和 22 例（18.5%）。单因素分析显示，IGFR1 高表达与所有患者的 PFS 和 OS 均较差显著相关。多因素分析显示，在 EGFR 突变的肺腺癌患者亚组中，IGFR1&VEGF-A 表达的患者 PFS 和 OS 最差。
这些结果表明，IGFR1&VEGF-A 可能是 EGFR 突变的早期和局部晚期肺腺癌患者预后不良的因素。此外，本研究可能为筛选早期和局部晚期肺腺癌患者联合抗 VEGF 和抗 IGFR1 治疗的最佳人群提供理论可能性。
Zotero 插件